Blueprint Medicines (BPMC) Tops Q3 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.20), $0.18 better than the analyst estimate of ($2.38). Revenue for the quarter came in at $56.56 million versus the consensus estimate of $50.66 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- eBay to cut 9% of workforce in strategic operational push, Reuters reports
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
